Nonalcoholic Fatty Liver Disease

Tyler Thrasher; Manal F Abdelmalek

doi:10.18043/ncm.77.3.216

Nonalcoholic Fatty Liver Disease

N C Med J. 2016 May-Jun;77(3):216-9. doi: 10.18043/ncm.77.3.216.

Authors

Tyler Thrasher¹, Manal F Abdelmalek²

Affiliations

¹ clinical trials assistant, Division of Gastroenterology and Hepatology, Department of Medicine, Duke University, Durham, North Carolina.
² associate professor of medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Duke University, Durham, North Carolina [email protected].

PMID: 27154894
DOI: 10.18043/ncm.77.3.216

Abstract

Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, is the leading cause of chronic liver disease. Treatments target lifestyle modification and improvement of underlying risk factors. Noninvasive biomarkers for diagnosis and staging of NAFLD and safe, cost-effective treatments for patients with nonalcoholic steatohepatitis (NASH) and/or NASH-related cirrhosis are currently under investigation.

MeSH terms

Humans
Non-alcoholic Fatty Liver Disease / diagnosis
Non-alcoholic Fatty Liver Disease / drug therapy*